April 30, 2025 | 11:00 - 11:45 AM ET / 17:00 - 17:45 CET
Join Value, Access and Pricing experts Max Hunt, Mary Fletcher-Louis and Pinar Bilir as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Companies throughout the life sciences industry are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Publication Access Form…
Published July 14, 2020
Executive Summary Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization Pharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely to…
A life science company engaged TGaS Advisors to: Investigate drivers for gender diversity in VP/SVP commercial roles Benchmark high-performing companies (in/ex industry) with above-average numbers of women in executive roles Benchmark the key competencies and skills of women in executive commercial roles Complete the form below to view the brief…
Published June 2, 2020
Executive Summary China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited to…
Trinity explores some of the immediate challenges presented to New Products Planning (also known as Early Commercial Planning or New Product Commercialization) groups. Publication Access Form…
While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace. How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world? Publication Access Form…
Highlights from Trinity’s Recent Research Focused on Telehealth Since earlier this year when the COVID-19 virus outbreak began and quickly made its way around the globe, the way in which we operate has changed. Virtual communication for personal as well as business interactions is on the rise. Publication Access Form…
Highlights from Trinity’s Recent Research Focused on European HCP The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. As the EU5 countries comprise some of the most important pharmaceutical markets, and with Italy, Spain and France includes countries which have been impacted significantly from COVID-19, Trinity aimed to understand the impact on HCP engagement with Market Research. Publication access form…
Perspectives from 50+ Industry Forecasting Leaders, Highlights from Trinity’s Recent Research Focused on BioPharma Forecasting In a time of peak uncertainty, forecasters are being called on to answer some of the industry’s toughest questions surrounding the impact of COVID-19. Trinity is bringing together the latest data on challenges forecasters have been experiencing over the past few weeks. This research activity is a joint project of Trinity’s Forecasting Center of Excellence and its benchmarking division, TGaS Advisors. Publication Access Form…
The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. The social distancing measures that are critically important to address the pandemic present new challenges with patient recruitment for clinical trials, market research, and drug launches. In this time of uncertainty, Trinity is assessing the impact on market research services including the ability of healthcare providers to participate in research. In its latest brief, “Impact of COVID-19 on Healthcare Market…
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
